Having a child with a rare disease fuels my passion for the promise of cell and gene therapies.
After 35 years in a career, I started experiencing what many professionals consider as “burn out.” That was 10 years ago. However, I fell into a role that exposed me to cell and gene therapy while working on logistic strategies for early phase clinical trials in oncology – unbeknownst this is precisely what renewed my interest and passion for work!
From an encounter with Dr. Carl June; hearing the story of Emily Whitehead and her family- it left an amazing and personal impact. I’m the mother of an adult child with a rare disease. I completely empathized with the promise of miracles this industry could provide to patients and their families: the ability to use the “C” word for a rare disease – CURE.
Ultra-rare diseases
My beautiful daughter Tanna has Type 3 Hereditary Angioedema. Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of swelling of the skin and / or mucous, which can also affect the gastrointestinal tract and upper airways in a severe way. The crisis does not respond to antihistamines, corticosteroids or adrenaline and usually disappear spontaneously within 12-72 hours. There is a mutation in the gene that encodes the C1 inhibitor of the complement factor (INHC1), inducing a reduction in its synthesis (type I HAE) or the formation of a dysfunctional protein (type II HAE).
But – as is typical of my daughter, she couldn’t just have HAE! She had to have the rarest form of HAE – Type 3. In 2000, a new subtype of HAE was identified that is clinically indistinguishable from the others and predominantly discovered in women where INHC1 is normal. The new disorder was called hereditary angioedema type III, estrogen-dependent hereditary angioedema or hereditary angioedema with normal C1 activity (type III HAE). And, we’ve now been dealing with it for 43 years!
Years and years of misdiagnosis and hundreds of trips to the emergency room is often typical
It wasn’t until 2002 that we received a proper diagnosis for Tanna’s condition. She was 24 years old and had her very first external swelling episode. She was driving from Houston back to her home in Colorado when her lips started to sting – her tongue started to swell – and then her lips became swollen beyond its normal state. She was about 2 hours outside of Denver in the middle of nowhere and called 911. They immediately dispatched her to a local hospital in Denver and started administering her with steroids (the exact opposite of what she needed!). This treatment option was non responsive; they started testing afraid her airway was going to close. It was something of a miracle that an ER doctor on call had just read an article on HAE – and recognized this could be the problem. After testing, rescue meds were administered and she ultimately left the hospital for the first time with an accurate diagnosis!
In the earlier years, Tanna’s swelling started internally. Starting around age eight, she would complain of stomach issues that would cause her to cry and appear to be in agonizing pain. We’d rush to the ER – where doctors could not find anything wrong with her. Doctor after doctor was consulted. But the extreme episodes happened numerous times a year; at one point when she was in her adolescence, I was told she was a hypochondriac seeking attention and they suggested psychological counselling. She insisted the pain was real! So we went on with intermittent ER visits where she would enter the hospital and go through tests – and the pain would go away.
Imagine how we felt years later – finally realizing she actually had a rare disease that was indeed causing internal swelling and pain – and that it was treatable!
Ongoing drug shortages – Challenges in finding knowledgeable experts
While the first, most important hurdle of proper diagnosis was crossed – there are still ongoing challenges with rare diseases. For HAE, there are only a handful of doctors who specialize in the disease and physician education and awareness is critical. Over the years, there have been international, US and social media foundations and groups organised in an effort to both create awareness and provide resources for patients, physicians and caretakers. It’s been a huge asset for us to have access to information and resources. Access to the right medications can be a struggle as there are often shortages of some of the treatments. Tanna self infuses once a month and has actually trained her 11 year old daughter to administer a rescue med should her airways begin to close.
Living a full life with a rare disease
Today, Tanna is a mother of 2 daughters and an ICU charge nurse. Since March 2020, she has worked in Houston running a Covid-19 ICU at a hospital organised to treat the inner city/urban community. She only lives 6 blocks from me – which she will tell you is both a blessing and a curse! But the grandgirls love that they can walk to Mimi’s house for pancakes every Saturday morning!
The promise of cell and gene therapy
As I mentioned above, I personally found my “calling” in cell and gene therapy. I joined ICON a year and a half ago specifically because of the work being done in CGT. I had been working with all CRO’s and was so impressed with the ICON Cell and Gene Therapy Center of Excellence I called ICON to see if there was a place for me. ICON can be very proud of the reputation and the services being provided for these programs to address unmet needs – to help bring the promise of cures and treatments to these patients!
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel